dasiglucagon vs Nasal Glucagon
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Severe Hypoglycemia
Shared mechanism: Glucagon receptor (agonist) · full Severe Hypoglycemia pipeline
dasiglucagon · Zegalogue
Rights held by Zealand Pharma and partners; US product discontinued
NCT03895697 · Phase 3 · completed
The trial randomized 92 participants and masked participants, care providers, investigators, and outcome assessors while comparing two dasiglucagon batches in a crossover design. Its primary measure was a physiological glucose-recovery endpoint rather than a hard clinical outcome, and no primary endpoint result is posted.
Reported efficacy
Time to Plasma Glucose Recovery (0-45 minutes after dosing): Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12) (met)
Result source: NCT03378635
Nasal Glucagon · Baqsimi
Marketed by Amphastar Pharmaceuticals, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Severe Hypoglycemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nasal Glucagon
show 2 more results
Available safety results
Nasal Glucagon
| Dropout rate | —3 mg NCT01556594 · Phase 2 · registry result, not featured evidence show 2 more results—2 mg NCT01556594 · Phase 2 · registry result, not featured evidence —1 mg NCT01556594 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —3 mg NCT01556594 · Phase 2 · registry result, not featured evidence show 2 more results—2 mg NCT01556594 · Phase 2 · registry result, not featured evidence —1 mg NCT01556594 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%3 mg NCT01556594 · Phase 2 · registry result, not featured evidence show 2 more results0%2 mg NCT01556594 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01556594 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 3 mg lacrimation increased 75% pallor 25% tremor 25% NCT01556594 · Phase 2 · registry result, not featured evidence show 2 more results2 mg lacrimation increased 50% headache 33.3% asthenia 27.8% NCT01556594 · Phase 2 · registry result, not featured evidence 1 mg hyperhidrosis 25% asthenia 16.7% catheter site bruise 16.7% NCT01556594 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dasiglucagon's landscape · Nasal Glucagon's landscape